Proove Biosciences Founder and CEO Brian Meshkin Wins 2014 SmartCEO Future 50 Award

• 

"On behalf of the hundreds of employees, partners, and researchers on the Proove team, I am honored to accept this award as a recognition of the tremendous accomplishments of our team" - Proove Biosciences, CEO, Brian Meshkin

IRVINE, CA and FULTON, MD (PRWEB) January 20, 2014

Proove Biosciences, the leading personalized pain medicine laboratory, today announces that its Chief Executive Officer and founder, Brian Meshkin, has been awarded SmartCEO’s prestigious Future 50 Award. The Future 50 Awards is the largest and most highly anticipated SmartCEO awards program. The program recognizes 50 fast-growth, mid-sized companies in the region. These companies represent the future of the region’s economy, and embody the entrepreneurial spirit critical for leadership and success.

As it states on the SmartCEO web page, “Every business dreams of growing — and growing fast. However, at a time when the news is dominated by healthcare debates, housing fallout and economic instability, it can be a feat simply to maintain the status quo. Yet the Future 50 winners profiled here managed to grow their businesses in spite of challenging times.”

SmartCEO goes onto explain, “When growth happens quickly, managing the change can be difficult. Strong leaders know when it’s time to hire additional staff and restructure business plans. Seasoned CEOs are flexible at a time when it is easy to become overwhelmed. The Future 50 company leaders succeed at making wise decisions that take business to the next level. While it is easy to play it safe, the Future 50 focus on taking risks. SmartCEO’s largest and most anticipated awards program of the year recognizes companies that have increased their revenue and expanded into new markets. These CEOs are expanding their businesses at a time when other companies are scaling back — or shutting their doors altogether.”

Continuing its explanation, SmartCEO states, “All of this year’s Future 50 winners have faced down challenges, overcome unforeseeable market shifts and dealt with professional and personal difficulties to lead their teams to incredible achievements. Each winner exemplifies the qualities of a great leader and understands the long process that comes with taking their business to the next level. The winners of this year’s Future 50 represent the area’s fast-growth companies, chosen based on a combined three-year average of revenue and employee growth.”

To see more of this publication, click here.

“On behalf of the hundreds of employees, partners, and researchers on the Proove team, I am honored to accept this award as a recognition of the tremendous accomplishments of our team. Having started this company in the heart of the Great Recession, it’s fun to look back and realize we have been very blessed to experience dramatic growth and success,” stated Proove Biosciences founder and CEO, Brian Meshkin. “This has only been possible through our team’s hard work and dedication to our mission and Proove Promise.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

PDF Print